News

Dr. C. Hubert Chan, Chief Medical Officer of Lyvgen Biopharma: Innovation in Clinical Development for the Breakthrough Cancer Immunotherapy of Next-Generation IO Agonistic Antibodies

Lyvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapies, announced the appointment of Hubert Chan, M.D., Ph.D., as Senior Vice President and Chief Medical Officer. Dr. Chan oversees the clinical development of Lyvgen's lead candidates LVGN6051 (a new generation of CD137 or 4-1BB agonistic monoclonal antibody (mAb)) and LVGN7409 (a new generation of CD40 agonistic mAb), as well as other novel IO agonistic pipelines. Dr. Chan shared a recent exciting news of Lyvgen clinical program that the first patient was dosed in the phase I clinical trial of LVGN7409 (CD40 agonistic mAb) and LVGN3616 (PD-1 blocker mAb) combination therapy for the treatment of patients with advanced relapsed cancer. Both of the antibodies are in-house developed by Lyvgen. This clinical milestone is a major achievement for Lyvgen, and is expected to bring new treatment options to more patients.

July, 2022

Lyvgen Biopharma Announces Publication of “Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking” in Frontiers in Pharmacology

Lyvgen announced publication of a review under the research topic of Targeting TNF/TNFR Signaling Pathways in Frontiers in Pharmacology, the second most-cited journal in its field advances access to pharmacological discoveries to prevent and treat human disease.
The review entitled “Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking” summarizes the biological function of Tumor Necrosis Factor Receptor Superfamily (TNFRSF) members, the landscape of TNFRSF agonistic clinical antibody candidates, and the important regulation role of FcγRIIB cross-linking for the antitumor activities of the therapeutic agonists. The authors expand the rationale and relative evidences of Lyvgen’s xLinkAb platform technology for developing tumor microenvironment avidity-driven TNFRSF agonistic antibodies. This work was published in collaboration with Oncology Bio-informatics expert, Professor Guanglei Zhuang, and his team at the Key Laboratory of Oncogenes and Related Genes, Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, China.

July 5, 2022

Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting

Shanghai, Suzhou, 4 June, 2021--Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a virtual format from June 4 to 8, 2021.

The Trials in Progress poster presentation summarizes the safety profile, antitumor activity observed in a phase I clinical trial (NCT04130542) in collaboration with Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada. The trial is evaluating LVGN6051, a second generation 4-1BB (CD137) agonist antibody based on Lyvgen proprietary xLinkAb platform, as monotherapy or in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in adult patients with advanced malignancies. No MTD was reached at 7 mg/kg monotherapy and 4 mg/kg q3w monotherapy was determined as RP2D. Preliminary antitumor activity in late stage cancer patients was observed. Combination with pembrolizumab induced rapid antitumor responses in advanced cancer patients with immune-cold tumor or relapsed from prior immunotherapies.

June 4, 2021

Lyvgen Biopharma Completes Series C Funding Led by IDG Capital

February23, 2021 - Lyvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it has completed Series C founding. This round of financing was led by IDG Capital and included Shanghai FTZ Fund, Suzhou Longmen Venture Capital, CHENGWEI Capital and others, with China Renaissance Group as the exclusive financial adviser.

February 23, 2021

Lyvgen Announces First in Human Dosing of LVGN7409 CD40 Agonist Monoclonal Antibody in a Phase 1 Clinical Trial for the Treatment of Advanced or Metastatic Malignancy in the US

January 26, 2021 - Lyvgen, a clinical-stage biotechnology company, today announced first-in-human (FIH) dosing of its xLinkAb product LVGN7409 (CD40 agonist), a bi-functional monoclonal antibody optimally activating CD40 upon FcγRIIB-mediated cross-linking.

January 26, 2021

Lyvgen Appoints Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development

Suzhou, China, October 19, 2020 – Lyvgen Biopharma, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, is pleased to announce today the appointment of Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development. This appointment forms part of Lyngen’s strategic drive to strengthen CMC capabilities including GMP manufacturing.

October 19, 2020

Lyvgen Biopharma (Suzhou) officially opened in BioBAY, Suzhou, China.

Lyvgen Biopharma (Suzhou) officially opened in BioBAY on June 10, 2020. Founded by Dr. Jieyi Wang in 2016, Lyvgen focuses on the development of novel immune-oncology (IO) agonist antibodies. At present, the company has built an CMC center of 2,000 square meters of therapeutic antibodies in BioBAY, Suzhou, China. The company headquarters, R&D center and GMP production site are also under active preparation. Follow us on Linkedlin.

June 10, 2020

Lyvgen Announces Clinical Trial Collaboration With MSD

Phase 1 clinical trials evaluating LVGN6051 second generation 4-1BB (CD137) agonist antibody and KEYTRUDA® (pembrolizumab) for the treatment of multiple types of cancer.

June 09, 2020

Lyvgen announced, through its fully owned subsidiary Lyvgen Biopharma (Suzhou), the successful GMP-compliant production of LVGN7409

May 2020

Phase 1 Trial of LVGN6051 as Single Agent and in Combination Therapy in Advanced or Metastatic Malignancy

October 2019